Advancements in the molecular pathogenesis of myelodysplastic syndrome

Current Opinion in Hematology

Volumn 16, Issue 2, 2009, Pages 70-76

  Epling Burnette, Pearlie K ^a,b,c   List, Alan F ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Department of Malignant Hematology ^*  (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aging; DNA repair; Genetic instability; Microenvironment; Myelodysplasia

Indexed keywords

CASPASE 8; CYCLOSPORIN; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; INTERLEUKIN 1; LENALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW; CHROMOSOMAL INSTABILITY; CHROMOSOME 5Q; DRUG MECHANISM; ERYTHROPOIESIS; GENE MUTATION; GENOMIC INSTABILITY; HEREDITY; HUMAN; MICROENVIRONMENT; MOLECULAR CLONING; MORBIDITY; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TELOMERE;

ANIMALS; DISEASE PROGRESSION; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 62249219784     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283257ac7     Document Type: Review

References (82)

1. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112:45-52. This article reports the incidence of MDS and chronic myeloproliferative disorders (CMDs) on the basis of population-based cancer registries in the United States. Representing approximately 82% of the US population with more than 40 000 observations reported, this study represents the largest ever reported in MDS.
2. Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007; 109:1536-1542.
3. De Roos AJ, Deeg HJ, Davis S. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. Cancer Causes Control 2007; 18:1199-1208.
4. Aul C, Giagounidis A, Germing U, et al. Myelodysplastic syndromes. Diagnosis and therapeutic strategies. Med Klin (Munich) 2002; 97:666-676.
5. Radlund A, Thiede T, Hansen S, et al. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 1995; 54:153-156.
6. Maynadie M, Verret C, Moskovtchenko P, et al. Epidemiological characteristics of myelodysplastic syndrome in a well defined French population. Br J Cancer 1996; 74:288-290.
7. Yue G, Hao S, Fadare O, et al. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res 2008; 32:553-558.
8. Killick SB, Mufti G, Cavenagh JD, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003; 120:679-684.
9. Ganser A, Passweg J, Stadler M, et al. Immunosuppressive treatment strategies in low-risk MDS. Cancer Treat Rev 2007; 33 (Suppl 1):S11-S14.
10. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37:15-29.
11. Saad ST, Vassallo J, Arruda VA, et al. The role of bone marrow study in diagnosis and prognosis of myelodysplastic syndrome. Pathologica 1994; 86:47-51.
12. Tuzuner N, Cox C, Rowe JM, et al. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 1995; 91:612-617.
13. Goyal R, Qawi H, Ali I, et al. Biologic characteristics of patients with hypocellular myelodysplastic syndromes. Leuk Res 1999; 23:357-364.
14. Marisavljevic D, Cemerikic V, Rolovic Z, et al. Hypocellular myelodysplastic syndromes: clinical and biological significance. Med Oncol 2005; 22:169-175.
15. Cermak J, Michalova K, Brezinova J, et al. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk Res 2003; 27:221-229.
16. Mohamedali A, Gaken J, Twine NA. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110:3365-3373.
17. Sokal G, Michaux JL, Van Den Berghe H, et al. A new hematologic syndrome with a distinct karyotype: the 5q chromosome. Blood 1975; 46:519-533.
18. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352:549-557.
19. List AF. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). Semin Oncol 2005; 32:331-S35.
20. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008; 451:335-339. An RNA-mediated interference (RNAi)-based approach was used to replicate the partial loss of genes in 5q- syndrome. The authors identified a novel linkage with a ribosomal subunit protein RPS14 and bone marrow failure in 5q- syndrome. Finally, this work describes the molecular pathophysiology of the 5q- syndrome in relationship to Diamond-Blackfan anemia.
21. Willig TN, Draptchinskaia N, Dianzani I, et al. Mutations in ribosomal protein S19 gene and diamond blackfan anemia: wide variations in phenotypic expression. Blood 1999; 94:4294-4306.
22. Draptchinskaia N, Gustavsson P, Andersson B, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet 1999; 21:169-175.
23. Gazda HT, Grabowska A, Merida-Long LB, et al. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet 2006; 79:1110-1118.
24. Liu JM, Ellis SR. Ribosomes and marrow failure: coincidental association or molecular paradigm? Blood 2006; 107:4583-4588.
25. McGowan KA, Li JZ, Park CY, et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet 2008; 40:963-970.
26. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111:86-93.
27. Ebert BL, Galili N, Tamayo P. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008; 5:e35.
28. Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007; 35:1739-1746.
29. Zang DY, Goodwin RG, Loken MR, et al. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001; 98:3058-3065.
30. Claessens YE, Park S, Dubart-Kupperschmitt A, et al. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood 2005; 105: 4035-4042.
31. Benesch M, Platzbecker U, Ward J, et al. Expression of FLIP(Long) and FLIP(Short) in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia 2003; 17:2460-2466.
32. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998; 103:176-188.
33. Aizawa S, Nakano M, Iwase O, et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 1999; 23:239-246.
34. Deeg HJ, Beckham C, Loken MR, et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 2000; 37:405-414.
35. Cortelezzi A, Fracchiolla NS, Mazzeo LM, et al. Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodys-plastic syndromes. Leuk Lymphoma 2005; 46:1345-1351.
36. Marcondes AM, Mhyre AJ, Stirewalt DL, et al. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci U S A 2008; 105:2865-2870.
37. Stirewalt DL, Mhyre AJ, Marcondes M, et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol 2008; 140:444-453.
38. Kim SH, Han SY, Azam T, et al. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005; 22:131-142.
39. Goda C, Kanaji T, Kanaji S, et al. Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 2006; 18:233-240.
40. Conti P, Youinou P, Theoharides TC. Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun Rev 2007; 6:131-137.
41. Epling-Burnette PK, Bai F, Painter JS, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007; 109:4816-4824.
42. Saunthararajah Y, Molldrem JL, Rivera M, et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol 2001; 112:195-200.
43. Sloand EM, Kim S, Fuhrer M, et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 2002; 100:4427-4432.
44. Kook H, Zeng W, Guibin C, et al. Increased cytotoxic T cells with effector phenotype in aplastlc anemia and myelodysplasia. Exp Hematol 2001; 29:1270-1277.
45. Epling-Burnette PK, Painter JS, Rollison DE, et al. Prevalence and clinical association of clonal T-cell expansions in myelodysplastic syndrome. Leukemia 2007; 21:659-667.
46. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003; 102:3025-3027.
47. Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99:699-705.
48. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is over-represented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100:1570-1574.
49. Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26:2505-2511.
50. Sloand EM, Mainwaring L, Fuhrer M, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106:841-851.
51. Sloand EM, Pfannes L, Chen G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 2007; 109:2399-2405.
52. Varga G, Kiss J, Varkonyi J, et al. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Pathol Oncol Res 2007; 13:311-319.
53. Powers MP, Nishino H, Luo Y, et al. Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch Pathol Lab Med 2007; 131:1789-1793.
54. Fuhler GM, Drayer AL, Olthof SG, et al. Reduced activation of protein kinase B, Rac, and F-actin polymerization contributes to an impairment of stromal cell derived factor-1 induced migration of CD34+ cells from patients with myelodysplasia. Blood 2008; 111:359-368.
55. Fuhler GM, Hooijenga F, Drayer AL, Vellenga E. Reduced expression of flavo-cytochrome b558, a component of the NADPH oxidase complex, in neutrophils from patients with myelodysplasia. Exp Hematol 2003; 31:752-759.
56. Rassool FV, Gaymes TJ, Omidvar N, et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res 2007; 67:8762-8771. This study describes a two-step mouse model of leukemic progression serving as the molecular basis of MDS pathogenesis. Mutant NRAS and BCL2 genes increased the frequency of DNA damage leading to an increased frequency of error-prone repair of double-strand breaks and an increase in reactive oxygen species.
57. Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 2008; 112:965-974.
58. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008; 87:515-526.
59. Guillem V, Tormo M. Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk Lymphoma 2008; 49:204-217.
60. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108:419-425.
61. Starczynowski DT, Vercauteren S, Telenius A, et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008; 112:3412-3424.
62. Suela J, Alvarez S, Cigudosa JC. DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes. Cytogenet Genome Res 2007; 118:304-309.
63. Evers C, Beier M, Poelitz A, et al. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chromosomes Cancer 2007; 46:1119-1128.
64. Gohring G, Karow A, Steinemann D, et al. Chromosomal aberrations in congenital bone marrow failure disorders: an early indicator for leukemogenesis? Ann Hematol 2007; 86:733-739.
65. Paulsson K, Heidenblad M, Strombeck B, et al. High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia 2006; 20:840-846.
66. Gondek LP, Dunbar AJ, Szpurka H, et al. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS ONE 2007; 2:e1225.
67. Gondek LP, Tiu R, O'Keefe CL, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008; 111:1534-1542.
68. Gondek LP, Haddad AS, O'Keefe CL, et al. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp Hematol 2007; 35:1728-1738.
69. Mohamedali A, Gaken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110:3365-3373.
70. Tiu R, Gondek L, O'Keefe C, Maciejewski JP. Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia 2007; 21:1648-1657.
71. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 2004; 104:1474-1481.
72. Nucifora G, Begy CR, Kobayashi H, et al. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci U S A 1994; 91:4004-4008.
73. Robinson L, Robson L, Sharma P, et al. A novel dicentric deleted chromosome 21 arising from tandem translocation. Cancer Genet Cytogenet 2000; 121: 208-211.
74. Imai O, Kurokawa M, Izutsu K, et al. Mutational analyses of the AML1 gene in patients with myelodysplastic syndrome. LeukLymphoma2002; 43:617-621.
75. Harada H, Harada Y, Niimi H, et al. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004; 103:2316-2324.
76. Nucifora G, Birn DJ, Espinosa R 3rd, et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood 1993; 81:2728-2734.
77. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 2004; 23:4284-4296.
78. Kirschnerova G, Tothova A, Babusikova O. Amplification of AML1 gene in association with karyotype, age and diagnosis in acute leukemia patients. Neoplasma 2006; 53:150-154.
79. Niimi H, Harada H, Harada Y, et al. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia 2006; 20:635-644.
80. Watanabe-Okochi N, Kitaura J, Ono R, et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008; 111:4297-4308. This study describes a murine bone marrow transplantation model expressing mutations of the transcription factor AML1/RUNX1 that are commonly associated with MDS/AML. Depending on the integration site of the AML1 mutant and the specific mutation, some mice developed pancytopenia and erythroid dysplasia, whereas others developed an AML-like phenotype. This manuscript therefore demonstrates the molecular basis of the heterogeneous phenotype observed in MDS and provides a mechanism for leukemia progression.
81. Omidvar N, Kogan S, Beurlet S, et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res 2007; 67:11657-11667. This study describes two in-vivo models of mutant NRas and BCL-2 overexpression in mouse. One model involves a tetracycline regulated transgene expression and a constitutive model in which both NRas and BCL-2 are expressed by the myeloid-specific MRP8 promoter. The results demonstrate the relationship between expression of these proteins and leukemia progression.
82. Zhang Y, Rowley JD. Chromatin structural elements and chromosomal translocations in leukemia. DNA Repair (Amst) 2006; 5:1282-1297.